Ascletis Pharma Inc. has announced that it will present the study results of two drug candidates, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ in Chicago, U.S., scheduled from June 20 to 23, 2025. The presentations will include a poster on ASC30, an oral GLP-1R small molecule agonist, which is the subject of a first-in-human single ascending dose study in participants with obesity. Additionally, a separate poster will feature ASC47, a muscle-preserving weight loss drug candidate, which demonstrated superior weight loss in combination with Semaglutide compared to Semaglutide monotherapy in a preclinical model. Both presentations are set for June 22, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.